There is a 'valley of death' in European research and innovation, says CEO of Novo Nordisk Foundation ...
By Nikhil Sharma and Pranav Kashyap (Reuters) -European shares rose on Tuesday, buoyed by gains in the healthcare and luxury ...
One of the hottest growth areas in the healthcare landscape these days is the obesity drug market because of a class of drugs ...
Few drugs have generated as much excitement as Novo Nordisk's (NYSE: NVO) Ozempic and Wegovy. In June 2021, Novo Nordisk won ...
As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...
The team categorized pediatric obesity treatment response, based on changes in body mass index standard deviation score, as ...
The Stoxx Europe 600 hit a record high on Wednesday, in the latest sign of bullish sentiment among global investors. The broad-based European index rose 0.6 per cent to 529.14, led by stocks in the ...
The pan-European STOXX 600 was up 0.5%, as of 0822 GMT, and trading at its highest level since Sept. 27, 2024. Heavyweight ...
Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...
A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues, including ...
Adults with obesity receiving once-weekly semaglutide 7.2 mg lost a higher proportion of their body weight at 72 weeks than ...
For several decades, the prevalence of steatotic liver disease (SLD) has been steadily increasing.1 Alterations in hepatic ...